The role of statins in reducing the risk of no-slow-reflow by coronary revascularisation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Blood flow restoration by percutaneous coronary intervention (PCI) is currently one of the main approaches to the treatment of patients with acute myocardial infarction. However, suboptimal coronary reperfusion associated with microvascular obstruction (no-slow-reflow phenomenon) may occur in 30–60% of cases after PCI. This review presents an analysis of the effect of statin therapy on the risk of no-slow-reflow and clinical prognosis in patients after PCI.

Full Text

Restricted Access

About the authors

A. Khripunova

Stavropol State Medical University

Author for correspondence.
Email: fktcz2007@yandex.ru

Associate Professor, Candidate of Medical Sciences

Russian Federation, Stavropol

G. Sazanov

Stavropol regional clinical hospital

Email: fktcz2007@yandex.ru
Russian Federation, Stavropol

I. Znamenskaya

Stavropol State Medical University

Email: fktcz2007@yandex.ru

Candidate of Medical Sciences

Russian Federation, Stavropol

I. Khripunova

Stavropol State Medical University

Email: fktcz2007@yandex.ru

Associate Professor, Candidate of Medical Sciences

Russian Federation, Stavropol

References

  1. Vyshlov E.V., Ryabov V.V. Coronary reperfusion in acute myocardial infarction. Tomsk: Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 2019; 196 р. (in Russ.).
  2. Writing Committee Members, Lawton JS, Tamis-Holland JE, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79 (2): e21–e129. doi: 10.1016/j.jacc.2021.09.006
  3. Ibanez B., James S., Agewall S. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018; 39: 119–77. doi: 10.1093/eurheartj/ehx393
  4. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985; 312 (14): 932–6. doi: 10.1056/NEJM198504043121437
  5. Niccoli G., Kharbanda R.K., Crea F. et al. No-reflow: Again prevention is better than treatment. Eur Heart J. 2010; 31 (20): 2449–55. doi: 10.1093/eurheartj/ehq299
  6. Kaul S. The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options. J Cardiol. 2014; 64 (2): 77–85. doi: 10.1016/j.jjcc.2014.03.008
  7. Iskhakov M.M., Tagirova D.R., Gazizov N.V. et al. «No-Reflow» Phenomenon: Clinical Aspects of Reperfusion Failure. Kazan Medical Journal. 2015; 96 (3): 391–6 (in Russ.). doi: 10.17750/KMJ2015-391
  8. Tasar O., Karabay A.K., Oduncu V. et al. Predictors and outcomes of no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coron Artery Dis. 2019; 30 (4): 270–6. doi: 10.1097/MCA.0000000000000726
  9. Niccoli G., Burzotta F., Galiuto L. et al. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009; 54 (4): 281–92. doi: 10.1016/j.jacc.2009.03.054
  10. De Waha S., Patel M.R., Granger C.B. et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: An individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017; 38 (47): 3502–10. doi: 10.1093/eurheartj/ehx414
  11. Caiazzo G., Musci R.L., Frediani L. et al. State of the Art: No-Reflow Phenomenon. Cardiol Clin. 2020; 38 (4): 563–73. doi: 10.1016/j.ccl.2020.07.001
  12. Kaur G., Baghdasaryan P., Natarajan B. et al. Pathophysiology, Diagnosis, and Management of Coronary No-Reflow Phenomenon. Int J Angiol. 2021; 30 (1): 15–21. doi: 10.1055/s-0041-1725979
  13. Riksen N.P., Franke B., van den Broek P. et al. The 1976C>T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genom. 2007; 17 (7): 551–4. doi: 10.1097/FPC.0b013e32803fb78f
  14. Kloner R.A., King K.S., Harrington M.G. No-reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018; 315 (3): H550-H562. doi: 10.1152/ajpheart.00183.2018
  15. Faruk Akturk I., Arif Yalcin A., Biyik I. et al. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction. Minerva Cardioangiol. 2014; 62 (5): 389–97.
  16. Theilmeier G., Verhamme P., Dymarkowski M. et al. Hypercholesterolemia in minipigs impairs left ventricular response to stress: association with decreased coronary flow reserve and reduced capillary density. Circulation. 2002; 106 (9): 1140–6. doi: 10.1161/01.cir.0000026805.41747.54
  17. Patti G., Pasceri V., Colonna G. et al. Atorvastatin pretreatment im-proves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49 (12): 1272–8. doi: 10.1016/j.jacc.2007.02.025
  18. Yun K.H., Jeong M.H., Oh S.K. et al. The beneficial effect: of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2009; 137 (3): 246–51. doi: 10.1016/j.ijcard.2008.06.055
  19. Ishii H., Ichimiya S., Kanashiro M. et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther. 2006; 28 (11): 1812–9. doi: 10.1016/j.clinthera.2006.11.003
  20. Chang S.M., Yazbek N., Lakkis N.M. Use of statins prior to percutane¬ous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv. 2004; 62 (2): 193–7. doi: 10.1002/ccd.20078
  21. Yun K.H., Shin I.S., Shin S.N. et al. Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention. Korean Circ J. 2011; 41 (8): 458–63. doi: 10.4070/kcj.2011.41.8.458
  22. Briguori C., Colombo A., Airoldi F. et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004; 25 (20): 1822–8. doi: 10.1016/j.ehj.2004.07.017
  23. Ebrahimi R., Saleh J., Toggart E. et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol. 2008; 20 (6): 292–5.
  24. Ray K.K., Cannon C.P., McCabe C.H. et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005; 46 (8): 1405–10. doi: 10.1016/j.jacc.2005.03.077
  25. Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285 (13): 1711–7. doi: 10.1001/jama.285.13.1711
  26. Kim J.-S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: The STATIN STEMI trial. JACC Cardiovasc. Interv. 2010; 3 (3): 332–9. doi: 10.1016/j.jcin.2009.11.021
  27. Spencer F.A., Allegrone J., Goldberg R.J. et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004; 140 (11): 857–66. doi: 10.7326/0003-4819-140-11-200406010-00006
  28. Bauer T., Böhm M., Zahn R. et al. Effect of chronic statin pretreatment on hospital outcome in patients with acute non-ST-elevation myocardial infarction. J Cardiovasc Pharmacol. 2009; 53 (2): 132–6. doi: 10.1097/FJC.0b013e3181976a3c
  29. Annibali G., Scrocca I., Aranzulla T.C. et al. «No-Reflow» Phenomenon: A Contemporary Review. J Clin Med. 2022; 11 (8): 2233. doi: 10.3390/jcm11082233
  30. Alidoosti M., Lotfi R., Lotfi-Tokaldany M. et al. Correlates of the «No-Reflow» or «Slow-Flow» Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention. J Tehran Heart Cent. 2018; 13 (3): 108–14.
  31. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21 (11): 1712–9. doi: 10.1161/hq1101.098486
  32. Sposito A.C., Chapman M.J. Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol. 2002; 22 (10): 1524–34. doi: 10.1161/01.atv.0000032033.39301.6a
  33. Kurita A., Takashima H., Ando H. et al. Effects of eicosapentaenoic acid on peri-procedural (type IVa) myocardial infarction following elective coronary stenting. J Cardiol. 2015; 66 (2): 114–9. doi: 10.1016/j.jjcc.2014.09.004
  34. Prasad A., Herrmann J. Myocardial infarction due to percutaneous coronary intervention. N Engl J Med. 2011; 364 (5): 453–64. doi: 10.1056/NEJMra0912134

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies